Asmanex HFA
(mometasone nasal inhalation)Phase 3Small molecule
Sumitomo Pharma America, Inc.Mometasone is a corticosteroid inhaled medication used to prevent asthma symptoms such as difficulty breathing, chest tightness, wheezing, and coughing. It works by reducing swelling and irritation in the airways to help you breathe more easily.[1] Asmanex HFA is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Asmanex HFA is one of 27 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
271 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Sudafed
KKenvue Brands
Phase 3
Asmanex HFA
Sumitomo Pharma America, Inc.Phase 3
Ciclesonide HFA
Sumitomo Pharma America, Inc.Phase 3
EMS Acarbose
EEMS
Phase 3
Asmanex
NovartisPreclinical
HL151
HHanlim Pharm. Co., Ltd.
Phase 3
Veramyst
GSKPreclinical
Singulair
AstraZenecaPreclinical
Xolair
RochePreclinical
Bilaxten
MMenarini International Operations Luxembourg SA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mometasone nasal inhalation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details